title: Therapeutic potential of anticytokine therapy in congestive heart failure.
abstract: Accumulating evidence indicates that inflammatory cytokines play a pathogenic role in congestive heart failure (CHF) by influencing heart contractility, inducing hypertrophy, and promoting apoptosis or fibrosis, contributing to the continuous myocardial remodeling process. While several stimuli may be operating such as heat-shock protein, microbial antigen, bacterial lipopolysaccharide, shear and oxidative stress, hypoxia and oxidized low-density lipoprotein (LDL), it seems that the inflammatory response to these stimuli may represent a common final pathogenic pathway in CHF regardless of the initial event. Traditional cardiovascular drugs seem to have little influence on the overall cytokine network, and immunomudulatory therapy has emerged as a possible new treatment modality in CHF. Several animal studies, and some clinical pilot studies, have suggested that down-regulation of inflammatory cytokines may improve cardiac performance. On the other hand, preliminary results from the placebo-controlled studies suggest no effect, or even adverse effect, of antitumor necrosis factor (TNF) therapy on mortality and hospitalization. Although somewhat disappointing, these negative results do not necessarily argue against the 'cytokine hypothesis'. These studies just underscore the difficulties and the challenges in developing treatment modalities that can modulate the cytokine network in CHF patients resulting in anti-inflammatory and beneficial net effects. Further research in this area will have to more precisely identify the most important actors in the immunopathogenesis of CHF in order to develop more specific immunomodulating agents for this disorder. However, at present the beneficial role of anticytokine therapy in patients with CHF remains unproven.
authors.affiliation: Section of Clinical Immunology and Infectious Diseases, Rikshospitalet, Oslo, NorwayResearch Institute for Internal Medicine, Rikshospitalet, Oslo, Norway. pal.aukrust@rikshospitalet.no
authors.forename: Pal
authors.initials: P
authors.lastname: Aukrust
authors.forename: Arne
authors.initials: A
authors.lastname: Yndestad
authors.forename: Jan K
authors.initials: JK
authors.lastname: Damås
authors.forename: Lars
authors.initials: L
authors.lastname: Gullestad
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism*; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism* / Q000503:physiopathology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000276:immunology / Q000627:therapeutic use; D007167:Immunotherapy; D018836:Inflammation Mediators / Q000276:immunology / Q000378:metabolism*; D012720:Severity of Illness Index
chemical_list: D016207:Cytokines; D016756:Immunoglobulins, Intravenous; D018836:Inflammation Mediators